吸烟者纤维化IIP的CT评分预测UIP特征及进展
本研究回顾性纳入两个经活检证实的吸烟纤维化特发性间质性肺炎队列(推导组242例,验证组126例),基于三种HRCT征象构建U-I-P评分(0-3分)。结果显示U-I-P评分在两组中均可独立预测组织病理学UIP特征(AUC分别为0.83和0.89,均p<0.001),且在验证组中可独立预测1年及2年疾病进展。
要点
- U-I-P评分含上肺不规则线、胸膜面不规则、基底部胸膜下网状影三项,适用于CT表现不典型或无法活检的吸烟纤维化IIP患者。
- 该评分可预测吸烟合并UIP型纤维化患者的疾病进展风险,有助识别高危人群。
- 评分操作简便,基于常规HRCT征象,适合在日常阅片中直接应用。
核心结论
- U-I-P评分在吸烟纤维化IIP患者中可检出组织病理学UIP特征,并预测疾病进展,是一种实用的影像生物标志物,即使CT表现为不典型类型亦适用。
研究设计与样本
- 回顾性多中心研究,含两个经活检证实的吸烟纤维化IIP队列:推导组242例(全国性登记),验证组126例(单中心数据库,2008-2013年)。
- 研究对三种预定义HRCT征象进行评分,并通过logistic回归、ROC分析、Cox比例风险模型和bootstrap内部验证评估与病理UIP特征及结局的关联。
关键影像表现/征象
- U-I-P评分由三种征象组成:上肺不规则线(U)、胸膜面不规则(I)、基底部胸膜下网状影(P),每项0/1分,总分0-3分。
- 推导组208/242例(86%)和验证组109/126例(87%)存在组织病理学UIP特征。
诊断标准与关键数值
- U-I-P评分在推导组预测病理UIP特征的AUC为0.83(p<0.001),验证组AUC为0.89(p<0.001)。
- U-I-P评分在验证组独立预测1年疾病进展(p=0.002)和2年疾病进展(p=0.001)。
- bootstrap验证显示模型乐观度极小,支持模型稳定性。
临床应用与阅片要点
- 在活检不可行或CT表现不提示典型UIP时,可用U-I-P评分帮助识别吸烟者中的UIP型纤维化及进展高风险患者。
- 阅片时需重点观察上肺不规则线、胸膜面不规则及基底部胸膜下网状影三项征象并分别赋分。
局限性
- 验证队列为单中心数据库,研究对象仅有吸烟的纤维化IIP患者。
- 研究为回顾性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Histopathological usual interstitial pneumonia (UIP) features are associated with progressive fibrosis but may be overlooked in smokers, where emphysema and smoking-related fibrosis complicate CT-based UIP classification. This study aimed to develop and validate a CT-based score to detect histopathological UIP features and to evaluate its association with disease progression in smokers with fibrotic idiopathic interstitial pneumonia (IIP).
MATERIALS AND METHODS: This retrospective multicentre study included two biopsy-proven cohorts of smokers with fibrotic IIP: derivation (n = 242; nationwide registry) and validation (n = 126; single-centre database, 2008-2013). Three predefined HRCT findings-upper-lobe irregular lines (U), irregularity of pleural surface (I), and pleural-based basal reticulation (P)-were scored (0/1) and summed as the U-I-P score (0-3). Associations with histopathological UIP features and outcomes were assessed using logistic regression, receiver operating characteristic analysis, Cox proportional hazards models, and bootstrap internal validation.
RESULTS: Cohorts were similar (median age 65 vs. 64 years; 88% vs. 87% male). Histopathological UIP features were present in 208/242 (86%) and 109/126 (87%) patients. The U-I-P score independently predicted histopathological UIP features in both cohorts (area under the curve, 0.83 and 0.89; both p < 0.001). Bootstrap validation demonstrated minimal optimism, supporting model stability. The U-I-P score independently predicted disease progression at 1 and 2 years in the validation cohort (p = 0.002 and p = 0.001, respectively).
CONCLUSION: The U-I-P score detects histopathological UIP features and predicts disease progression in smokers with fibrotic IIP, providing a practical imaging biomarker, even in cases with atypical CT patterns.
KEY POINTS: Question: In smokers with fibrotic interstitial lung disease, emphysema and smoking-related fibrosis complicate CT pattern classification, limiting identification of usual interstitial pneumonia pathology.
FINDINGS: The U-I-P (upper-lobe irregular lines, irregularity of pleural surface, pleural-based reticulation) score detected histopathological usual interstitial pneumonia features and predicted progression.
CLINICAL RELEVANCE: The U-I-P score aids identification of smokers with usual interstitial pneumonia-type fibrosis and increased risk of progression when biopsy is unavailable, or CT patterns are atypical for usual interstitial pneumonia.
引用
- Egashira, Fujimoto, Kataoka, et al. A CT-based score for predicting histopathological usual interstitial pneumonia features and predicting disease progression in smokers with fibrotic idiopathic interstitial pneumonia. Eur Radiol. 2026. PMID: 42470480. doi:10.1007/s00330-026-12741-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。